These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 30657070)

  • 41. Biologic therapies in the spondyloarthritis: new opportunities, new challenges.
    Braun J; Brandt J; Listing J; Rudwaleit M; Sieper J
    Curr Opin Rheumatol; 2003 Jul; 15(4):394-407. PubMed ID: 12819466
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Golimumab improves patient-reported outcomes in daily practice of inflammatory rheumatic diseases in Germany.
    Krueger K; Remstedt S; Thiele A; Hohenberger S
    J Comp Eff Res; 2020 Aug; 9(12):891-902. PubMed ID: 32722921
    [No Abstract]   [Full Text] [Related]  

  • 43. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Emery P; Keystone EC; Schiff MH; van Riel PL; Weinblatt ME; Weisman MH
    Ann Rheum Dis; 2006 Nov; 65 Suppl 3(Suppl 3):iii2-15. PubMed ID: 17038465
    [No Abstract]   [Full Text] [Related]  

  • 44. Acute and long-term effect of infliximab on humoral and echocardiographic parameters in patients with chronic inflammatory diseases.
    Tomáš L; Lazúrová I; Pundová L; Oetterová M; Zakuciová M; Petrášová D; Studenčan M
    Clin Rheumatol; 2013 Jan; 32(1):61-6. PubMed ID: 23010850
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Educational session as a tool to increase patient satisfaction of switching etanercept from the prefilled syringe to the autoinjection pen.
    Borrás-Blasco J; Gracia-Pérez A; Casterá MD; Rosique-Robles JD; Abad J
    Expert Opin Biol Ther; 2013 Aug; 13(8):1103-8. PubMed ID: 23675687
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Psoriasis onset during infliximab treatment: description of two cases.
    Volpe A; Caramaschi P; Carletto A; Pieropan S; Bambara LM; Biasi D
    Rheumatol Int; 2006 Oct; 26(12):1158-60. PubMed ID: 16738903
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology.
    Lequerré T; Vittecoq O; Klemmer N; Goëb V; Pouplin S; Menard JF; Daragon A; Mejjad O; Le Loët X
    J Rheumatol; 2006 Jul; 33(7):1307-14. PubMed ID: 16758513
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model.
    Crandall WV; Mackner LM
    Aliment Pharmacol Ther; 2003 Jan; 17(1):75-84. PubMed ID: 12492735
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study.
    Van Assche G; Vermeire S; Noman M; Amant C; Weyts E; Vleminckx A; Vermeyen MJ; Rutgeerts P
    J Crohns Colitis; 2010 Sep; 4(3):329-33. PubMed ID: 21122522
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).
    Colebatch AN; Marks JL; Edwards CJ
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008872. PubMed ID: 22071858
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biologics in Inflammatory and Immunomediated Arthritis.
    Luchetti MM; Benfaremo D; Gabrielli A
    Curr Pharm Biotechnol; 2017; 18(12):989-1007. PubMed ID: 29278210
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases.
    Han C; Smolen JS; Kavanaugh A; van der Heijde D; Braun J; Westhovens R; Zhao N; Rahman MU; Baker D; Bala M
    Arthritis Res Ther; 2007; 9(5):R103. PubMed ID: 17922913
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.
    Minozzi S; Bonovas S; Lytras T; Pecoraro V; González-Lorenzo M; Bastiampillai AJ; Gabrielli EM; Lonati AC; Moja L; Cinquini M; Marino V; Matucci A; Milano GM; Tocci G; Scarpa R; Goletti D; Cantini F
    Expert Opin Drug Saf; 2016 Dec; 15(sup1):11-34. PubMed ID: 27924643
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Biologicals in the treatment of rheumatic diseases].
    Scherer HU; Burmester GR
    Dtsch Med Wochenschr; 2006 Oct; 131(41):2279-85. PubMed ID: 17036270
    [No Abstract]   [Full Text] [Related]  

  • 55. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
    Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
    Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
    Chastek B; White J; Van Voorhis D; Tang D; Stolshek BS
    Adv Ther; 2016 Apr; 33(4):626-42. PubMed ID: 26970958
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry.
    Glintborg B; Sørensen IJ; Loft AG; Lindegaard H; Linauskas A; Hendricks O; Hansen IMJ; Jensen DV; Manilo N; Espesen J; Klarlund M; Grydehøj J; Dieperink SS; Kristensen S; Olsen JS; Nordin H; Chrysidis S; Dalsgaard Pedersen D; Sørensen MV; Andersen LS; Grøn KL; Krogh NS; Pedersen L; Hetland ML;
    Ann Rheum Dis; 2017 Aug; 76(8):1426-1431. PubMed ID: 28473425
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study.
    Schmitz EMH; Benoy-De Keuster S; Meier AJL; Scharnhorst V; Traksel RAM; Broeren MAC; Derijks LJJ
    Clin Rheumatol; 2017 Sep; 36(9):2129-2134. PubMed ID: 28593609
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study.
    Benucci M; Gobbi FL; Bandinelli F; Damiani A; Infantino M; Grossi V; Manfredi M; Parisi S; Fusaro E; Batticciotto A; Sarzi-Puttini P; Atzeni F; Meacci F
    Immunol Res; 2017 Feb; 65(1):419-422. PubMed ID: 27449503
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience.
    Fantò M; Peragallo MS; Pietrosanti M; Di Rosa R; Picchianti Diamanti A; Salemi S; D'Amelio R
    Intern Emerg Med; 2016 Feb; 11(1):31-40. PubMed ID: 26099279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.